The CD4+ and CD8+ T cell populations in splenocytes in FeMOF-based cancer vaccines in large size (dLLC-ML) and small size (dLLC-MS) are significantly higher than saline group and free dLLC autologous tumor antigens group (Figure 6). The gene discussed is CD8A; the disease is cancer.